ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
With FDA’s Approval of the Second Biosimilar, Humira to Fight for the Glory of King!
September 01, 2017There comes the second FDA-approved biosimilar of AbbVie’s branded drug Humira (adalimumab), as the tumor necrosis factor (TNF) blocker Cyltezo of Boehringer Ingelheim was approved for marketing by FDA on August 25. -
More Canadians have access to HUMIRA for the treatment of Ulcerative Colitis
August 30, 2017HUMIRA® (adalimumab) now reimbursed in British Columbia, Ontario, New Brunswick, Newfoundland and Labrador, Saskatchewan and Yukon, it's also covered by the federal Non-Insured Health Benefits (NIHB) program.
Pharma Sources Insight January 2025
